Abstract
Summary Cervical screening aims to reduce the incidence of and death rate from cervical cancer. The death rate is currently dropping by 7% per annum in the UK owing to a cervical screening programme testing women every 3–5 years up to 65 years of age. Human papillomavirus infection appears to be intimately involved in the development of cervical dysplasia and progression to carcinoma. The management of abnormal smears reflects this relationship. Colposcopy as a secondary screen is used to investigate defined cytological abnormalities and to treat high-grade preinvasive or early invasive disease. Thereafter, more frequent cervical smears are required to detect treatment failure or recurrent dysplasia. Various aspects of the screening programme are integrated by quality assurance surveillance procedures, ensuring that all disciplines perform to appropriate and acceptable standards. Liquid-based cytology is being introduced, and human papillomavirus testing is currently undergoing evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
